Big play of the year! Gautejia boss "home ugly" led to The Mystery of Boya Bio's $800 million deal

Text . . On the evening of September 10th Linan, the entire pharmaceutical industry was eating the "melons" of The Goodyear boss.
An "open letter to every Gottjia" circulated on the Internet, focusing on the medical and health industry investment of Gautejia Group Chairman Cai Dajian private affair exposed, his married wife Kim a report that he and his former subordinates have long maintained an improper relationship, and also used the company's power to fight her divorce lawsuit. the
open letter also mentioned that Cai Dajian is addicted to the relationship with Zhang, did not have the time and energy to take into account the work of the cause, resulting in GaoTejia 2017 so far operating mismanagement, resulting in major mergers and acquisitions out of control (such as the Danxia project, etc.), the company's employees should have the benefit bonus was canceled.
2001, GaoTejia was founded in Shenzhen, and its early investment projects involved various industries.
2007, Cai Dajian proposed a "theme industry investment" model, focusing on health care, Gao Tejia began to embark on the path of specialization.
at present, The size of Gaotejia's asset management has exceeded 20 billion yuan, 24 health care industry funds, has invested in more than 140 enterprises, including more than 70 medical and health enterprises, and promoted the listing of 15 enterprises.
Among them, the investment projects involve many well-known enterprises, such as Meirui Medical, Danxia Bio, Co-Shadow Medical, Fuhong Hanxuan, Via Bio, Chinese Antibodies, Kangfang Bio, Erno, Boosais, Tian Guangxi, Changfeng Pharmaceuticals and so on.
's acquisition of Danxia, mentioned in the above-mentioned open letter, is out of control, not a hole in the wind, and also involves Another listed company of Gauteja Investment, Boya Bio.
800 million yuan in 2007, Cai Dajian Investment owned Boya Bio.
Boa bio-business involved in blood products business, Tian'an Pharmaceuticals diabetes drug business, Xin bai Pharmaceuticals biochemical drug business.
promoted by Gotja, Boya Bio landed on the GEM in 2012 and set a precedent for Chinese private equity firms to control listed companies.
Danxia Bio was established in April 2002, the main blood products production and sales.
information released by the company, Gautejia Group and Boya Bio jointly set up an investment partnership, Ex-Sea Premium.
April 2017, Mae Haiyou acquired a 99% stake in Danxia Bio (Boya Guangdong).
danxia biological business scope includes production and sales: blood products (human haemoglobin, human immunoglobulin, hepatitis B human immunoglobulin) and so on.
July 2, 2019, Danxia Bio changed its name to Boya Biopharmaceuticals (Guangdong) Co., Ltd., which has a competitive relationship with Boya Bio.
And in the same year that The former Haiyou acquired Danxia Bio, the State Food and Drug Administration organized a flight inspection of Danxia Bio for the drug GMP, which found that the aluminum ions of human haemoglobin were higher than the standard of the Chinese Pharmacopoeia.
the above-mentioned acts have violated the Drug Administration Law of the People's Republic of China and related regulations, the Guangdong Food and Drug Administration withdrew the Drug GMP Certificate (CN20130057) and suspended production.
to the industry's bewilderment, just after Danxia Bio was ordered to suspend production, Boya Bio is still paying a large advance to Danxia Bio, and Danxia Bio has not been delivered.
May 2017, Boya Bio disclosed that it intends to allocate plasma and plasma components to Danxia Biosourcing, with a total contract value of not more than 402 million yuan.
In April 2019, in the case of an advance payment of more than 300 million yuan and the failure to obtain plasma, Boya Bio terminated the pre-contract with Danxia Bio and signed a new contract to purchase no more than 500 tons of raw plasma from Danxia Bio, with a purchase price of not more than 1.65 million yuan/ton and a contract value of not more than 825 million yuan.
2019, Boya Bio made an advance payment of 500 million yuan to Danxia Bio, but still failed to obtain plasma.
Bio's 2020 semi-annual report shows that by the end of June this year, Boa Bio's advance payment balance to Danxia Bio was 823 million yuan, with another 200,000 yuan in other receivables.
For Boya Bio's strange investment behavior, industry insiders said, Gaotejia and Boya Bio jointly invested in the acquisition of Danxia Bio, in addition to Boya Bio invested 50 million yuan, other funds constitute the group used a large number of financial institutions and other funds.
to keep Boya Guangdong is crucial to the security of the Gothia Group's capital chain.
In addition, due to the competing relationship between Boya Bio and Danxia Bio, Gauteja issued a letter of commitment in 2017 to give priority to the acquisition of a stake in Boya Guangdong by Boya Bio or its subsidiaries under the same conditions to resolve the issue of competition between the two companies.
However, Gao Tejia, on the grounds that "the operating time is short, nearly three years are in a loss-making state, the current integration of Boya Bio into Boa Guangdong conditions are not yet mature", will resolve the competition between the industry until December 31, 2021.
Therefore, the industry speculated that Boa bio is so close to Danxia biological, because the future of the high probability will buy Danxia biological, that is, after the name of Boya Guangdong, so more than 800 million "transfusion" or financial support.
Shenzhen Stock Exchange inquiry Boya Bio suspected to be easy to master Boya Bio's abnormal investment behavior has also received the attention of Shenzhen Stock Exchange.
In June this year, Shenzhen Stock Exchange sent a letter of inquiry to Boya Bio, asking for information on the reasons and reasonableness of the large advance payments made by the company between 2017 and 2018, and the reasons and reasonableness of the advance payment of 500 million yuan to Boya (Guangdong) in 2019.
to this, Boya Bio replied that although Guangdong Boya's GMP certificate was withdrawn, the pulping practices of its affiliated plasma stations have been legal and compliant, and the pulping volume of these plasma stations is higher than the industry average.
company's payment to Guangdong Boya is to support the collection of its raw plasma and normal operating expenses, there is no financial support for Guangdong Boya.
recently, Boya Bio has also been caught up in the rumors, net rumors that "China Resources Capital intends to consider the acquisition of a controlling stake in Boya Bio, and has held preliminary talks with Boya Bio's majority shareholder Shenzhen Gaotejia Investment Group."
, and a number of shareholders, among others, are frequently reducing their stakes in Boya Bio.
September 4th, Boya Bio's shareholder, Shanghai Gaote Jiaxuan Investment Partnership (Limited Partnership), reduced its holdings by 14.6852 million shares between May 8, 2020 and September 4, 2020, reducing its shares by 3.45 percent and not holding shares in the company after the change of interests; Boya Bio previously announced that the controlling shareholder, Shenzhen Gaotejia Investment Group Co., Ltd., is planning major matters related to the company's equity changes.
, the matter is still in the planning stage, with some uncertainty.
Weibo netizens pointed out that at this time, The chairman of Gautejia original distribution difficulties, or in order to seize the external capital to buy a controlling stake in Boya Bio, if the chairman and the original allocation can not be reconciled, the transfer of equity will also be affected.
2015-2019, Boa Bio's net sales margin was 30.75 percent, 29.32 percent, 24.99 percent, 19.79 percent and 15.20 percent, respectively, according to Wind.
in the first half of this year, Boa Bio's financial results showed that during the reporting period, the company achieved total operating income of RMB1.33 billion and realized operating profit of RMB200 million, down 21% from a year earlier, while net profit attributable to shareholders of listed companies was RMB161 million, down 24.4% from a year earlier.
800 million blood transfusions, a number of shareholders to reduce their holdings... The future direction of Boya's creatures is also of great concern.
was affected by the open letter incident, On September 11th Boa Bio's shares weakened, and by midday the day's close, Boya Bio's shares were down 4.17 per cent.